Andrew Arno Purchases 12,500 Shares of OncoCyte Co. (NASDAQ:OCX) Stock

OncoCyte Co. (NASDAQ:OCX) Director Andrew Arno purchased 12,500 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was acquired at an average price of $2.11 per share, for a total transaction of $26,375.00. Following the completion of the transaction, the director now directly owns 81,554 shares of the company’s stock, valued at approximately $172,078.94. This trade represents a 18.10 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

OncoCyte Stock Performance

Shares of OCX stock opened at $2.13 on Friday. OncoCyte Co. has a one year low of $1.98 and a one year high of $3.82. The company’s fifty day moving average price is $2.66 and its 200-day moving average price is $2.91.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The business had revenue of $0.12 million for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. During the same quarter in the previous year, the company posted ($0.57) earnings per share. Equities research analysts predict that OncoCyte Co. will post -2.57 EPS for the current fiscal year.

Institutional Trading of OncoCyte

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC grew its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 103,980 shares of the company’s stock after buying an additional 11,289 shares during the period. Geode Capital Management LLC owned 0.62% of OncoCyte worth $296,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 55.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on OCX. StockNews.com started coverage on OncoCyte in a report on Thursday. They issued a “sell” rating on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.25 price objective on shares of OncoCyte in a research note on Wednesday, November 13th.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.